In particular, perturbations in type-1 and type-2 cannabinoid receptors (CB1 and CB2) as well as in the main enzyme that terminates eCB signaling (i.e., the fatty acid amide hydrolase (FAAH); EC 3.5.1.99) have been reported in most brain regions that are involved in AD, as well as in the peripheral blood of AD patients [5,6,7]. Here, CNR1 is linked to Alzheimer disease.